Medicus Pharma submits streamlined Phase 2b/3 Teverelix trial design to FDA
AI Summary- Medicus Pharma submitted a streamlined Teverelix trial design to the FDA.
- The Phase 2b/3 study targets advanced prostate cancer patients with increased cardiovascular risk.
- Teverelix is being developed as a long-acting GnRH antagonist, with dose optimization included.